Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01287247 · ClinicalTrials.gov registry record
Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States
A clinical trial, sponsored by Merz North America.
- Completed
- Registry status
- 688
- Enrollment target
NCT01287247: Completed study, sponsored by Merz North America.
NCT01287247 is a clinical trial that has completed, run by Merz North America. The registered enrollment target is 688 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01287247 has completed, sponsored by Merz North America.
- COMPLETED
- Registry status
- 688 participants
- Enrollment target
Study Summary
This is a prospective, observational trial evaluating the "real world" use of Xeomin®(incobotulinumtoxinA). Physicians may enroll patients who are eligible to be treated with a botulinum toxin for cervical dystonia or blepharospasm based upon their clinical experience. The physician must have chosen to treat the patient with Xeomin® (incobotulinumtoxinA) prior to and independent of enrollment in this study. Physicians may choose to treat their subjects with up to 2 treatment cycles (approximately 6 months/subject) of Xeomin® (incobotulinumtoxinA) at a dose determined by the physician based upon his/her clinical experience with botulinum toxin. According and dependent on clinical practice, the investigators expect that subjects will be seen by the investigator for an average of 3 visits (two treatment cycles).
Primary Outcome
To collect, evaluate and report observational data about the clinical use of Xeomin® in a "real world" setting to determine injection patterns and use of guidance techniques.
Interventions
- BIOLOGICAL Xeomin®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 688 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-04 |
What the finished NCT01287247 record still lists
NCT01287247 is an observational study that tracks outcomes without assigning an intervention. The registered 688 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Xeomin® is the first listed.
NCT01287247 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01287247 about?
NCT01287247 is a clinical study titled "Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States". This is a prospective, observational trial evaluating the "real world" use of Xeomin®(incobotulinumtoxinA). Physicians may enroll patients who are eligible to be treated with a botulinum toxin for cervical dystonia or blepharospasm based upon their clinical experience. The physician must have chosen...
What is the current status of trial NCT01287247?
This trial is currently completed. The enrollment target is 688 participants. The study started on 2011-02. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01287247?
The interventions under investigation include: Xeomin® (BIOLOGICAL).
Who is sponsoring clinical trial NCT01287247?
This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05750654 · 688 participants · NA
Effectiveness of Small Phlebotomy Tubes in Reducing Blood Transfusions in Adult Medical Intensive Care Unit and Intermediate Care Unit Patients With Anemia
- NCT00532051 · 690 participants
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
- NCT05184335 · 690 participants · Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- NCT07221149 · 690 participants · Phase 2
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia